GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » Price-to-Tangible-Book

Humacyte (Humacyte) Price-to-Tangible-Book : 33.95 (As of Jun. 02, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Humacyte Price-to-Tangible-Book?

As of today (2024-06-02), Humacyte's share price is $7.47. Humacyte's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $0.22. Hence, Humacyte's Price to Tangible Book Ratio of today is 33.95.

The historical rank and industry rank for Humacyte's Price-to-Tangible-Book or its related term are showing as below:

HUMA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.86   Med: 6.11   Max: 33.95
Current: 33.95

During the past 4 years, Humacyte's highest Price to Tangible Book Ratio was 33.95. The lowest was 1.86. And the median was 6.11.

HUMA's Price-to-Tangible-Book is ranked worse than
96.89% of 1221 companies
in the Biotechnology industry
Industry Median: 2.79 vs HUMA: 33.95

A closely related ratio is called PB Ratio. As of today, Humacyte's share price is $7.47. Humacyte's Book Value per Sharefor the quarter that ended in Mar. 2024 was $0.22. Hence, Humacyte's P/B Ratio of today is 33.95.


Humacyte Price-to-Tangible-Book Historical Data

The historical data trend for Humacyte's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte Price-to-Tangible-Book Chart

Humacyte Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
- 6.11 1.86 21.68

Humacyte Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.90 4.84 8.18 21.68 14.14

Competitive Comparison of Humacyte's Price-to-Tangible-Book

For the Biotechnology subindustry, Humacyte's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humacyte's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humacyte's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Humacyte's Price-to-Tangible-Book falls into.



Humacyte Price-to-Tangible-Book Calculation

Humacyte's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=7.47/0.22
=33.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Humacyte Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Humacyte's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Humacyte (Humacyte) Business Description

Traded in Other Exchanges
N/A
Address
2525 East North Carolina Highway 54, Durham, NC, USA, 27713
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Executives
Laura E Niklason director, 10 percent owner, officer: President, CEO and Director 35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan director, 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Ayabudge Llc 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Heather Ledbetter Prichard officer: Chief Operating Officer 820 BROWNWICH STREET, WAKE FOREST NC 27587
Michael T. Constantino director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Dale A. Sander officer: CFO & CCDO 11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
William John Scheessele officer: Chief Commercial Officer 620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao officer: Chief Regulatory Officer 12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green director 3185 SCENIC DRIVE, NAPA CA 94558
Gordon M Binder director 225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Diane Seimetz director JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh officer: Chief Medical Officer 1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla director EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
William Edward Tente officer: Chief Regulatory Officer 90 DAVIS STREET, SEEKONK MA 02771
Todd Pope director C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713

Humacyte (Humacyte) Headlines